Previous 10 | Next 10 |
Investor presentation to highlight novel gene therapies for cancer and diabetes Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients wi...
Today, we are posting our first look at a small biotech concern called Genprex. Genprex has two early-stage drug candidates that are targeting NSCLC and diabetes. A full analysis follows in the paragraphs below. For further details see: Taking A Gander At Genprex
Companhia Brasileira de Distribuicao (CBD) -76%.Soleno Therapeutics (SLNO) -26% after providing update on DCCR for the treatment of Prader-Willi syndromeSify Technologies (SIFY) -15%.Luokung Technology (LKCO) -15% after receipt of Nasdaq notification letter and a request for emergen...
Investor presentations to highlight novel gene therapies for cancer and diabetes Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients w...
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced it has entered into securities purchase agreements with tw...
Genprex ([[GNPX]] +21.3%) announces the formation of a Clinical Advisory Board ((CAB)) to support its oncology and diabetes development programs.The CAB will lead and advise Genprex as it advances its REQORSA immunogene therapy program, including its Acclaim clinical trials in non-s...
World reknowned medical and clinical experts to guide Genprex’ novel gene therapy clinical development programs in cancer and diabetes, including its two upcoming clinical trials in lung cancer Genprex, Inc. (“Genprex” or the “Company”)...
Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations PR Newswire NEW YORK , Feb. 8, 2021 ...
Joins Global Movement to Raise Awareness and Reduce the Burden of Cancer Worldwide Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients...
Genprex shares rise ([[GNPX]] +6.5%) after the clinical-stage gene therapy company lists out its 2020 achievements and expected milestones for the year in a letter to its shareholders.The progress on the company's Acclaim-1 and Acclaim-2 trials evaluating REQORSA separately in combinatio...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...